Targets › AGER
2 programs from 2 companies in 5 trials: 3 Phase 2, 2 Phase 1; Infectious disease, Oncology, Respiratory; next expected readout Dec 2026.
Cell surface pattern recognition receptor that senses endogenous stress signals with a broad ligand repertoire including advanced glycation end products, S100 proteins, high-mobility group box 1 protein/HMGB1, amyloid beta/APP oligomers, nucleic acids, histones, phospholipids and glycosaminoglycans. Advanced glycation end products (AGEs) are nonenzymatically glycosylated proteins which accumulate in vascular tissue…. (UniProt, Q15109)
Open in Phaseline: the race on AGER, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Cantex Pharmaceuticals | Azeliragon Advanced glycosylation end product-specific receptor antagonist | AGER | Phase 2 | Glioblastoma; COVID-19; Cancer Related Cognitive Decline; Solid Tumor | Dec 2026 |
| Arrowhead Pharmaceuticals | ARO-RAGE RAGE antagonist / inhibitor | AGER | Phase 2 | Asthma | Dec 2027 |
Glioblastoma (1) COVID-19 (1) Cancer Related Cognitive Decline (1) Solid Tumor (1) Asthma (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.